Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Protagonist Therapeutics, Inc.
PTGX
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.0B
$131.73
▲ +5.24%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$49.38 - $131.84
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 146.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary peptide drug discovery and development platform enabling oral and injectable delivery
- Strategic partnership with Janssen Biotech providing resources, expertise, and commercialization support
- Differentiated mechanism of action targeting specific integrins and hepcidin pathways with fewer side effects
Bear Case
2 risks
- Above-average volatility (beta 1.8).
- Extreme premium - high expectations embedded
Growth
Turning profitable
Advancement of rusfertide through Phase II trials for multiple blood disorder indications with large addressable markets
Value
Extreme premium - high expectations embedded
Momentum
Hot
+20.6% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PTGX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of $0.05 vs -$0.65 consensus (+107.7% surprise). Revenue of $56.4M vs $11.7M expected (+381.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+107.7%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+184%
-89%
+33%
+1%
-96%
+99%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$4.2M
$4.7M
$170.6M
$28.3M
$5.5M
$4.7M
$7.4M
$56.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
6.7%
Wall Street consensus
12 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
8%
Sell
0%
Median Price Target
$121.00
▼ -8.1% vs $131.73
Latest: TD Cowen · Jul 1, 2026
2 analysts covering